Skip to main content

Large subretinal hemorrhage after intravitreal bevacizumab (Avastin) for age-related macular degeneration.

Publication ,  Journal Article
Chieh, JJ; Fekrat, S
Published in: Ann Ophthalmol (Skokie)
2007

We report the development of a large subretinal hemorrhage 4 weeks after intravitreal bevacizumab in an 84-year-old male with 20/70 visual acuity caused by occult choroidal neovascularization from neovascular age-related macular degeneration in one eye that was treated with 1.25 mg of intravitreal bevacizumab.

Duke Scholars

Published In

Ann Ophthalmol (Skokie)

DOI

EISSN

1558-9951

Publication Date

2007

Volume

39

Issue

1

Start / End Page

51 / 52

Location

United States

Related Subject Headings

  • Vitreous Body
  • Vision Disorders
  • Retinal Hemorrhage
  • Ophthalmology & Optometry
  • Male
  • Macular Degeneration
  • Humans
  • Drug Administration Routes
  • Bevacizumab
  • Antibodies, Monoclonal, Humanized
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chieh, J. J., & Fekrat, S. (2007). Large subretinal hemorrhage after intravitreal bevacizumab (Avastin) for age-related macular degeneration. Ann Ophthalmol (Skokie), 39(1), 51–52. https://doi.org/10.1007/BF02697326
Chieh, Jenet J., and Sharon Fekrat. “Large subretinal hemorrhage after intravitreal bevacizumab (Avastin) for age-related macular degeneration.Ann Ophthalmol (Skokie) 39, no. 1 (2007): 51–52. https://doi.org/10.1007/BF02697326.
Chieh, Jenet J., and Sharon Fekrat. “Large subretinal hemorrhage after intravitreal bevacizumab (Avastin) for age-related macular degeneration.Ann Ophthalmol (Skokie), vol. 39, no. 1, 2007, pp. 51–52. Pubmed, doi:10.1007/BF02697326.

Published In

Ann Ophthalmol (Skokie)

DOI

EISSN

1558-9951

Publication Date

2007

Volume

39

Issue

1

Start / End Page

51 / 52

Location

United States

Related Subject Headings

  • Vitreous Body
  • Vision Disorders
  • Retinal Hemorrhage
  • Ophthalmology & Optometry
  • Male
  • Macular Degeneration
  • Humans
  • Drug Administration Routes
  • Bevacizumab
  • Antibodies, Monoclonal, Humanized